Incannex Healthcare (IXHL) Return on Sales (2024 - 2025)

Incannex Healthcare's (IXHL) quarterly Return on Sales came in at 5.45% in Q2 2025, down 11.0% quarter-over-quarter from 4.91% in Q4 2024.

Incannex Healthcare (IXHL) Return on Sales (2024 - 2025) Analysis & Trends

Incannex Healthcare has disclosed Return on Sales across 2 years of filings, most recently posting 5.45% for Q2 2025.

Return on Sales for Q2 2025 came in at 5.45%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was 5.45% (changed N/A YoY), and the FY2025 annual result was 5.45%, up 993.0% from the prior year.
Return on Sales came in at 5.45% for Q2 2025 at Incannex Healthcare, down from 4.91% in the prior quarter.
In the past five years, Return on Sales ranged from a high of 0.73% in Q3 2024 to a low of 5.45% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	0.00%
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	0.00%
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	0.00%
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	0.00%
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	0.00%
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	0.00%
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	-0.02%
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	0.00%
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	0.00%
10	Incannex Healthcare	45.81 Mn	45.81 Mn	-	-

Download Data